Takeda Pharmaceutical is inviting Australian researchers and companies to submit early-stage research proposals for neuroscience, oncology, gastroenterology and platform technology projects.
The COCKPI-T 2023 funding programme is calling for projects to submit applications to receive up to AUD $104,000 in research funding.
The funding programme, launched in Australia in 2018, provides researchers affiliated with universities, research institutes or companies to submit proposals for early-stage research projects that align with the company’s areas of therapeutic interest.
Takeda Pharmaceuticals is offering approx. AUD $104,000 (or up to JPY $10 million) in funding for therapeutics-oriented projects and approx. AUD $83,000 (or up to JPY $8 million) for platform technology-oriented projects. Successful applicants also have the opportunity to work closely with Takeda drug discovery experts to help build a robust preliminary proof of concept (PoC).
Through the program, Takeda is aiming to catalyse the translation of early-stage research into innovative therapeutics or drug discovery platforms, with the ultimate aim of strengthening Takeda’s early pipeline.
Proposals should outline the competitive advantage of the research over existing therapeutics or technologies, as well as timelines within the one-year project term. Proposals should also include any non-confidential preliminary data produced by the applicant and publicly available data or information.
Any researcher affiliated with a university, research institute or company located in Australia is eligible to apply. Applications close on 1 August, with the final winners announced on 14 November 2023.
For further details of the programme, including criteria, the application process and timelines, visit the COCKPI-T funding website.
Questions relating to the programme can be emailed to COCKPI-T@takeda.com.